vs
博士伦健康（BHC）与DXC Technology Co（DXC）财务数据对比。点击上方公司名可切换其他公司
DXC Technology Co的季度营收约是博士伦健康的1.1倍（$3.2B vs $2.8B），DXC Technology Co净利率更高（3.4% vs -3.7%，领先7.0%），博士伦健康同比增速更快（9.3% vs -1.0%），博士伦健康自由现金流更多（$403.0M vs $359.0M），过去两年博士伦健康的营收复合增速更高（14.0% vs -2.9%）
博士伦健康公司（Bausch Health）是一家业务多元化的北美跨国制药企业，全球总部位于加拿大魁北克省拉瓦尔，美国总部设在新泽西州布里奇沃特。公司专注于胃肠病、肝病、神经科、皮肤科、牙科、医疗美容等领域的药物研发、生产及销售，同时提供品牌药和仿制药产品，业务覆盖全球市场。
DXC Technology是总部位于美国弗吉尼亚州阿什本的跨国信息技术服务与咨询企业，为全球客户提供专业的IT解决方案及相关咨询服务，助力企业实现数字化转型、提升运营效率。
BHC vs DXC — 直观对比
营收规模更大
DXC
是对方的1.1倍
$2.8B
营收增速更快
BHC
高出10.2%
-1.0%
净利率更高
DXC
高出7.0%
-3.7%
自由现金流更多
BHC
多$44.0M
$359.0M
两年增速更快
BHC
近两年复合增速
-2.9%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.8B | $3.2B |
| 净利润 | $-103.0M | $107.0M |
| 毛利率 | — | — |
| 营业利润率 | 17.0% | 8.2% |
| 净利率 | -3.7% | 3.4% |
| 营收同比 | 9.3% | -1.0% |
| 净利润同比 | -205.1% | 87.7% |
| 每股收益（稀释后） | $-0.30 | $0.61 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BHCDXC
| Q4 25 | $2.8B | $3.2B | ||
| Q3 25 | $2.7B | $3.2B | ||
| Q2 25 | $2.5B | $3.2B | ||
| Q1 25 | $2.3B | $3.2B | ||
| Q4 24 | $2.6B | $3.2B | ||
| Q3 24 | $2.5B | $3.2B | ||
| Q2 24 | $2.4B | $3.2B | ||
| Q1 24 | $2.2B | $3.4B |
净利润BHCDXC
| Q4 25 | $-103.0M | $107.0M | ||
| Q3 25 | $179.0M | $36.0M | ||
| Q2 25 | $148.0M | $16.0M | ||
| Q1 25 | $-58.0M | $264.0M | ||
| Q4 24 | $98.0M | $57.0M | ||
| Q3 24 | $-85.0M | $42.0M | ||
| Q2 24 | $10.0M | $26.0M | ||
| Q1 24 | $-64.0M | $-200.0M |
营业利润率BHCDXC
| Q4 25 | 17.0% | 8.2% | ||
| Q3 25 | 23.1% | 8.0% | ||
| Q2 25 | 17.5% | 6.8% | ||
| Q1 25 | 12.2% | 7.3% | ||
| Q4 24 | 21.8% | 8.9% | ||
| Q3 24 | 12.7% | 8.6% | ||
| Q2 24 | 16.2% | 6.9% | ||
| Q1 24 | 13.1% | 8.2% |
净利率BHCDXC
| Q4 25 | -3.7% | 3.4% | ||
| Q3 25 | 6.7% | 1.1% | ||
| Q2 25 | 5.8% | 0.5% | ||
| Q1 25 | -2.6% | 8.3% | ||
| Q4 24 | 3.8% | 1.8% | ||
| Q3 24 | -3.4% | 1.3% | ||
| Q2 24 | 0.4% | 0.8% | ||
| Q1 24 | -3.0% | -5.9% |
每股收益（稀释后）BHCDXC
| Q4 25 | $-0.30 | $0.61 | ||
| Q3 25 | $0.48 | $0.20 | ||
| Q2 25 | $0.40 | $0.09 | ||
| Q1 25 | $-0.16 | $1.42 | ||
| Q4 24 | $0.24 | $0.31 | ||
| Q3 24 | $-0.23 | $0.23 | ||
| Q2 24 | $0.03 | $0.14 | ||
| Q1 24 | $-0.17 | $-1.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $1.7B |
| 总债务越低越好 | $20.8B | $3.1B |
| 股东权益账面价值 | $-554.0M | $3.1B |
| 总资产 | $26.4B | $13.2B |
| 负债/权益比越低杠杆越低 | — | 0.98× |
8季度趋势，按日历期对齐
现金及短期投资BHCDXC
| Q4 25 | $1.3B | $1.7B | ||
| Q3 25 | $1.3B | $1.9B | ||
| Q2 25 | $1.7B | $1.8B | ||
| Q1 25 | $1.1B | $1.8B | ||
| Q4 24 | $1.2B | $1.7B | ||
| Q3 24 | $719.0M | $1.2B | ||
| Q2 24 | $595.0M | $1.3B | ||
| Q1 24 | $733.0M | $1.2B |
总债务BHCDXC
| Q4 25 | $20.8B | $3.1B | ||
| Q3 25 | $21.0B | $2.4B | ||
| Q2 25 | $21.7B | $3.1B | ||
| Q1 25 | $21.5B | $3.0B | ||
| Q4 24 | $21.6B | $3.6B | ||
| Q3 24 | $21.5B | $3.8B | ||
| Q2 24 | $21.7B | $3.8B | ||
| Q1 24 | $22.1B | $3.8B |
股东权益BHCDXC
| Q4 25 | $-554.0M | $3.1B | ||
| Q3 25 | $-565.0M | $3.1B | ||
| Q2 25 | $-764.0M | $3.2B | ||
| Q1 25 | $-1.2B | $3.2B | ||
| Q4 24 | $-1.3B | $3.0B | ||
| Q3 24 | $-1.2B | $3.0B | ||
| Q2 24 | $-1.2B | $2.9B | ||
| Q1 24 | $-1.1B | $2.8B |
总资产BHCDXC
| Q4 25 | $26.4B | $13.2B | ||
| Q3 25 | $26.8B | $13.6B | ||
| Q2 25 | $27.3B | $13.4B | ||
| Q1 25 | $26.4B | $13.2B | ||
| Q4 24 | $26.5B | $13.0B | ||
| Q3 24 | $26.5B | $13.5B | ||
| Q2 24 | $26.5B | $13.4B | ||
| Q1 24 | $26.9B | $13.9B |
负债/权益比BHCDXC
| Q4 25 | — | 0.98× | ||
| Q3 25 | — | 0.77× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 1.22× | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | — | 1.36× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $495.0M | $414.0M |
| 自由现金流经营现金流 - 资本支出 | $403.0M | $359.0M |
| 自由现金流率自由现金流/营收 | 14.4% | 11.2% |
| 资本支出强度资本支出/营收 | 3.3% | 1.7% |
| 现金转化率经营现金流/净利润 | — | 3.87× |
| 过去12个月自由现金流最近4个季度 | $1.0B | $1.1B |
8季度趋势，按日历期对齐
经营现金流BHCDXC
| Q4 25 | $495.0M | $414.0M | ||
| Q3 25 | $405.0M | $409.0M | ||
| Q2 25 | $289.0M | $186.0M | ||
| Q1 25 | $211.0M | $315.0M | ||
| Q4 24 | $601.0M | $650.0M | ||
| Q3 24 | $405.0M | $195.0M | ||
| Q2 24 | $380.0M | $238.0M | ||
| Q1 24 | $211.0M | $280.0M |
自由现金流BHCDXC
| Q4 25 | $403.0M | $359.0M | ||
| Q3 25 | $314.0M | $365.0M | ||
| Q2 25 | $190.0M | $143.0M | ||
| Q1 25 | $96.0M | $238.0M | ||
| Q4 24 | $495.0M | $568.0M | ||
| Q3 24 | $334.0M | $154.0M | ||
| Q2 24 | $302.0M | $190.0M | ||
| Q1 24 | $129.0M | $242.0M |
自由现金流率BHCDXC
| Q4 25 | 14.4% | 11.2% | ||
| Q3 25 | 11.7% | 11.5% | ||
| Q2 25 | 7.5% | 4.5% | ||
| Q1 25 | 4.2% | 7.5% | ||
| Q4 24 | 19.3% | 17.6% | ||
| Q3 24 | 13.3% | 4.8% | ||
| Q2 24 | 12.6% | 5.9% | ||
| Q1 24 | 6.0% | 7.1% |
资本支出强度BHCDXC
| Q4 25 | 3.3% | 1.7% | ||
| Q3 25 | 3.4% | 1.4% | ||
| Q2 25 | 3.9% | 1.4% | ||
| Q1 25 | 5.1% | 2.4% | ||
| Q4 24 | 4.1% | 2.5% | ||
| Q3 24 | 2.8% | 1.3% | ||
| Q2 24 | 3.2% | 1.5% | ||
| Q1 24 | 3.8% | 1.1% |
现金转化率BHCDXC
| Q4 25 | — | 3.87× | ||
| Q3 25 | 2.26× | 11.36× | ||
| Q2 25 | 1.95× | 11.63× | ||
| Q1 25 | — | 1.19× | ||
| Q4 24 | 6.13× | 11.40× | ||
| Q3 24 | — | 4.64× | ||
| Q2 24 | 38.00× | 9.15× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
DXC
| GIS Segment | $1.6B | 50% |
| CES Segment | $1.3B | 40% |
| Insurance Segment | $321.0M | 10% |
